Immunovant Ownership | Who Owns Immunovant?


OverviewForecastFinancialsChartTranscripts

Immunovant Ownership Summary


Immunovant is owned by 35.94% institutional investors, 57.04% insiders, and 7.01% retail investors. Fmr is the largest institutional shareholder, holding 8.62% of IMVT shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 3.34% of its assets in Immunovant shares.

IMVT Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockImmunovant35.94%57.04%7.01%
SectorHealthcare Stocks 232.01%10.74%-142.75%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr14.73M8.62%$237.44M
Deep track capital, lp9.73M5.69%$156.83M
Vanguard group7.78M4.48%$197.75M
Blackrock4.92M3.56%$129.79M
Armistice capital5.84M3.42%$94.08M
Blackrock funding, inc. /de6.06M3.34%$154.00M
Baker bros. advisors lp5.46M3.19%$87.98M
T. rowe price investment management5.16M3.02%$83.25M
Morgan stanley4.85M2.67%$123.20M
Point72 asset management3.44M2.01%$55.49M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Alpine global management2.75M7.65%$44.41M
Superstring capital management lp341.35K5.42%$5.50M
Stempoint capital lp1.59M5.13%$25.62M
Deep track capital, lp9.73M4.38%$156.83M
Adar1 capital management2.24M3.39%$36.14M
Great point partners500.00K3.32%$8.06M
Exome asset management158.62K1.55%$2.56M
Two seas capital lp2.87M1.50%$72.88M
Armistice capital5.84M1.40%$94.08M
Prosight management, lp243.40K1.28%$6.19M

Top Buyers

HolderShares% AssetsChange
Morgan stanley4.85M0.01%2.89M
Adar1 capital management2.24M3.39%1.71M
Soleus capital management1.11M1.04%1.11M
Vanguard group7.78M0.00%952.50K
Jennison associates700.46K0.01%700.46K

Top Sellers

HolderShares% AssetsChange
Fmr14.73M0.01%-3.87M
T. rowe price investment management5.16M0.05%-1.71M
Paradigm biocapital advisors lp---1.36M
Viking global investors lp---1.11M
Franklin resources---984.06K

New Positions

HolderShares% AssetsChangeValue
Soleus capital management1.11M1.04%1.11M$28.22M
Jennison associates700.46K0.01%700.46K$17.81M
Norges bank637.95K0.00%637.95K$15.80M
Superstring capital management lp341.35K5.42%341.35K$5.50M
Balyasny asset management197.57K0.00%197.57K$3.16M

Sold Out

HolderChange
Reuter james wealth management-1.00
Physician wealth advisors-1.00
Twin peaks wealth advisors-3.00
Capital performance advisors llp-3.00
Nelson, van denburg & campbell wealth management group-11.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025165-16.24%62,414,346-34.42%351.16%93-4.12%40-23.08%
Sep 30, 20251915.52%94,495,463-1.81%551.74%93-6.06%512.00%
Jun 30, 2025178-15.64%96,201,3013.59%561.41%96-25.58%5019.05%
Mar 31, 20252122.42%94,119,77717.45%642.15%13023.81%43-30.65%
Dec 31, 2024197-3.90%76,056,919-3.29%511.80%1005.26%58-9.38%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl S6.80M3.34%8.18K
Fidelity Growth Compy Commingled Pl O4.45M3.04%196.00K
Fidelity Growth Company Fund5.02M2.47%210.43K
Vanguard Total Stock Mkt Idx Inv2.57M1.26%10.44K
Vanguard US Total Market Shares ETF2.12M1.25%2.26K
State Street® SPDR® S&P® Biotech ETF2.28M1.12%-12.21K
Vanguard Small Cap Index1.84M0.90%-1.61K
T. Rowe Price Small-Cap Stock1.74M0.85%-60.27K
T. Rowe Price US Small-Cap Core Equity1.74M0.85%-65.20K
iShares Russell 2000 ETF1.69M0.83%829.62K

Recent Insider Transactions


DateNameRoleActivityValue
Feb 25, 2026Gloria Melanie Chief Operating OfficerSell$24.19K
Feb 25, 2026Gloria Melanie Chief Operating OfficerSell$38.77K
Feb 25, 2026Gloria Melanie Chief Operating OfficerSell$27.22K
Jan 21, 2026Stout Jay S Chief Technology OfficerSell$51.46K
Jan 07, 2026Stout Jay S Chief Technology OfficerSell$1.48K

Insider Transactions Trends


DateBuySell
2026 Q1-6
2025 Q4112
2025 Q3-4
2025 Q2-5
2025 Q1117

IMVT Ownership FAQ


Who Owns Immunovant?

Immunovant shareholders are primarily institutional investors at 35.94%, followed by 57.04% insiders and 7.02% retail investors. The average institutional ownership in Immunovant's industry, Biotech Stocks , is 381.47%, which Immunovant falls below.

Who owns the most shares of Immunovant?

Immunovant’s largest shareholders are Fmr (14.73M shares, 8.62%), Deep track capital, lp (9.73M shares, 5.69%), and Vanguard group (7.78M shares, 4.48%). Together, they hold 18.79% of Immunovant’s total shares outstanding.

Does Blackrock own Immunovant?

Yes, BlackRock owns 3.56% of Immunovant, totaling 4.92M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 129.79M$. In the last quarter, BlackRock increased its holdings by 439.33K shares, a 9.81% change.

Who is Immunovant’s biggest shareholder by percentage of total assets invested?

Alpine global management is Immunovant’s biggest shareholder by percentage of total assets invested, with 7.65% of its assets in 2.75M Immunovant shares, valued at 44.41M$.

Who is the top mutual fund holder of Immunovant shares?

Fidelity Growth Compy Commingled Pl S is the top mutual fund holder of Immunovant shares, with 3.34% of its total shares outstanding invested in 6.8M Immunovant shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools